Relmada Therapeutics (RLMD) Tops Q2 EPS by 24c
Tweet
Share
E-mail
Get Alerts RLMD Hot Sheet
Join SI Premium – FREE
Relmada Therapeutics (NASDAQ: RLMD) reported Q2 EPS of ($0.59), $0.24 better than the analyst estimate of ($0.83). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .
For earnings history and earnings-related data on Relmada Therapeutics (RLMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UGI shares spike on reported KKR bid for the company
- IP Strategy Holdings (IPST) halted, news pending
- Venu Holding (VENU) PT Lowered to $8.70 at Freedom Broker
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
